Abstract: Pharmaceutical composition with a controlled release of a metabolically active sugar, especially glucose, consisting of pellets containing a pellet core and a pellet core coating, the substance of which consists in that the pellet core contains at least 50% by weight of the metabolically active sugar, related to the total weight of the pellet core, at least one osmotically active substance or a disintegrant in a total amount up to 50% by weight, related to the total weight of the pellet core, and possibly standard excipients, wherein the pellet core coating consists of a polymeric membrane comprising a polymer of a cellulose derivative and/or methacrylate derivative, the weight of the pellet core coating being 5-50% by weight, related to the total weight of the pellet and the pharmaceutical composition contains pellets with at least one of the four different release profiles of the metabolically active sugar.

Abstract: An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R? group wherein R and R? independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oil and/or in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oily substance, in which suspens

Abstract: An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally

Abstract: An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R? group wherein R and R? independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oil and/or in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oily substance, in which suspens

Abstract: A pharmaceutical composition for administration by injection, comprising a mixture of platinum complex of general formula (I), wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an -0-C(O)—R or -0-C(O)—R? group wherein R and R? independently of one another are a hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group, which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, and of at least one cyclodextrin and/or at least one cyclodextrin derivative, and optionally of at least one pharmaceutically acceptable excipient.

Abstract: The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R? group wherein R and R? independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, in a pharmaceutically acceptable hydrophilic or hydrophobic injection liquid phase, 100% of particles of the platinum complex of general formula I being o

Abstract: A pharmaceutical composition for rectal or vaginal application, characterized in that it contains as active substance the platinum complex of general formula wherein A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and a hydrophilic gel-forming base, comprising gelatin, water and glycerol.

Abstract: An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally

Abstract: A method of preparation of an oral solid dosage form with instant release of an active agent containing as the active agent finasteride characterized in that an aqueous suspension containing 5% to 50% by weight of finasteride, based on the total weight of the suspension, and 0.1 to 50% by weight of at least one anion surfactant, based on the weight of finasteride is milled in order to reach such distribution of particle size of finasteride that the size of 10% of particles does not exceed 2 ?m, the size of 50% of particles does not exceed 7 ?m, and the size of 90% of particles does not exceed 17 ?m, then the obtained aqueous suspension is sprayed to a fluid bed onto a solid particle hydrophilic carrier having such distribution of particle size that the size of 90% of particles exceeds 40 ?m and the size of 10 of particles exceeds 200 ?m, and the size of 99% of particles does not exceed 300 ?m.

Abstract: The invention relates to a pharmaceutical composition containing the platinum complex of formula (I) as an active substance where A, A?, B, B?, X and X? have specific meanings, in a mixture with at least one pharmaceutically acceptable excipient, characterized in that it is formed of a granulate with particles smaller than 0.5 mm in size prepared by wet granulation of a mixture of platinum complex of tetravalent platinum of formula (I) wetted by water, at least one neutral saccharide and at least one native and/or modified polysaccharide, being optionally contained in a capsule or a sack or being optionally pressed into the form of a tablet, while the surface of the granulate, the capsule or the tablet is optionally coated with a layer of at least one pharmaceutically acceptable substance enabling enterosolvent dissolution of the active substance in bowels only and/or at least one pharmaceutically acceptable substance enabling the controlled release of the active substance.